[How to manage anticoagulation in atrial fibrillation ablation]

W Amara1, D Mlayeh1

  • 1Unité de rythmologie, GHI Le Raincy-Montfermeil, 10, rue du Général-Leclerc, 93370 Montfermeil, France.

Annales De Cardiologie Et D'Angeiologie
|October 10, 2018
PubMed

Insights

Non-vitamin K oral anticoagulants (NOACs) are evaluated in atrial fibrillation ablation trials. This review summarizes key studies and guidelines for anticoagulation management in these patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Atrial fibrillation ablation requires careful anticoagulation management.
  • Non-vitamin K oral anticoagulants (NOACs) are increasingly studied for this indication.

Purpose of the Study:

  • To summarize randomized trials evaluating NOACs in atrial fibrillation ablation.
  • To review current European Society of Cardiology and EHRA guidelines on anticoagulation for ablation patients.

Main Methods:

  • Review of published randomized controlled trials (VENTURE AF, RE-CIRCUIT, AXAFA).
  • Inclusion of data from complementary studies (ABRIDGE J, AEIOU).
  • Analysis of European Society of Cardiology and European Heart Rhythm Association guidelines.

Main Results:

  • Multiple trials have assessed NOAC efficacy and safety in atrial fibrillation ablation.
  • Guidelines provide recommendations for anticoagulation management in this patient group.

Conclusions:

  • Evidence from trials supports the use of NOACs in atrial fibrillation ablation.
  • Guidelines offer a framework for optimal anticoagulation strategies.

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.9K
Amyloid Fibrils03:03

Amyloid Fibrils

6.4K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.4K
Fibril-associated Collagen01:11

Fibril-associated Collagen

Fibril-associated collagens are a type of collagens present in the extracellular matrix with interrupted triple helices or FACIT (Fibril-associated collagens interrupted triple-helices). FACIT help connect and attach the collagen fibrils with each other as well as with other proteins of the extracellular matrix.
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
3.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.9K
Tonsillitis II: Management01:26

Tonsillitis II: Management

This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
429